PGT-A vs PGT-M: What’s the Difference? Top IVF Technology & Success Rate Guide

Understanding the difference between PGT-A vs PGT-M is the first critical step in IVF planning. PGT-A screens for correct chromosome numbers (aneuploidy) to reduce miscarriage risk, while PGT-M targets specific inherited single-gene disorders like cystic fibrosis. This guide provides a side-by-side comparison, success rates, and a clear decision flowchart for intended parents.

Quick Snapshot: PGT-A vs PGT-M at a Glance

What Is the Difference Between PGT-A and PGT-M in IVF Treatment?

Preimplantation Genetic Testing (PGT) is a specialized technique that combines in vitro fertilization (IVF) with genetic testing of embryos before implantation. There are three main PGT types (PGT-A, PGT-M, PGT-SR), each serving a different purpose.

In PGT-A vs PGT-M, what roles do they play in IVF treatment is a significant difference. In essence, PGT-A looks at the number of chromosomes, while PGT-M looks for a specific, inherited gene mutation.

Understanding their differences is the first step toward making an informed, confident decision about your fertility care.

PGT-A: Screening for Aneuploidy (Chromosome Count)

PGT-A stands for Preimplantation Genetic Testing for Aneuploidy. A healthy human embryo should have 46 chromosomes, with 23 inherited from each parent.

However, the likelihood of forming embryos with an abnormal number of chromosomes rises dramatically with parental age. These embryos are called "aneuploid," and they are a leading cause of implantation failure and early miscarriage.

The beauty of PGT-A is that it helps your embryologist identify which embryos have the correct chromosome count, known as "euploid" embryos, giving you the best possible chance at a successful pregnancy.

Additionally, PGT-A does not require parents to undergo pre-test genetic screening, making it a widely accessible and convenient option for most individuals and couples pursuing assisted reproduction.

PGT-M: Detecting Single Gene Disorders

PGT-M, on the other hand, stands for Preimplantation Genetic Testing for Monogenic conditions.

Unlike the broad chromosome screening of PGT-A, PGT-M is a highly targeted genetic test designed to identify specific inherited single-gene conditions that run in a family. Common examples include cystic fibrosis, sickle cell anemia, and Huntington’s disease.

While PGT-A checks the overall number of chromosomes, PGT-M focuses on specific gene mutations. For this reason, the test is fully customized for each couple.

The process requires DNA samples from both partners, and in some cases, from affected family members. The laboratory then develops a personalized genetic probe to target and detect the specific familial gene mutation.

As a result, PGT-M requires several weeks of preparatory work before the start of the IVF cycle.

Step-by-Step Decision Guide: Which Test Is Right for You?

The question “PGT-A vs PGT-M, which one do I need?” comes down to your medical history. Use this chart to find your situation:

Indications for Use: When Do You Need PGT-A vs PGT-M?

Understanding the indications for use of PGT-A vs PGT-M is crucial to choosing the right test for your situation.

Indications for PGT-A

Clinical guidelines recommend PGT-A in several scenarios. According to the American Society for Reproductive Medicine (ASRM), PGT-A is particularly beneficial for women of advanced maternal age — typically 36 to 40 years. Additional indications include:

1. Recurrent pregnancy loss (especially after two or more miscarriages).

2. Multiple failed IVF cycles.

3. Previous pregnancy with a chromosomal abnormality.

4. Couples who wish to transfer a single embryo with greater confidence.

Indications for PGT-M

The ASRM committee opinion states that PGT-M can be offered to all patients with a confirmed single‑gene disorder who wish to avoid passing that condition to their children. Specific indications include:

1. Both partners are carriers of an autosomal recessive disorder (e.g., cystic fibrosis).

2. One partner carries an autosomal dominant disorder (e.g., Huntington's disease).

3. A family history of an X-linked condition (e.g., Duchenne muscular dystrophy).

4. Previous child with a genetic disorder.

PGT-A vs PGT-M Combined Testing: When Both Tests Are Recommended

In many cases, couples who qualify for PGT-M also benefit from concurrent PGT-A screening. After all, selecting an embryo that is both unaffected by the genetic mutation and chromosomally normal maximizes the chances of a live birth.

Can You Combine Both? The short answer is yes. Combined PGT-A and PGT-M testing is not only feasible but also widely adopted in modern fertility clinics.

A single embryo biopsy and one genetic counseling session suffice for both tests. On day 5 or 6 of development (the blastocyst stage), embryologists extract a few cells from the trophectoderm (the outer layer that develops into the placenta). These samples are then sent to a genetic lab for simultaneous dual analysis.

Labs usually use next-generation sequencing (NGS) to conduct both assessments: checking overall chromosome copy numbers for PGT-A, and tracing haplotype inheritance to detect targeted gene mutations for PGT-M.

Research has verified full consistency across all tested embryos, proving this combined approach is highly accurate and reliable.

Benefits and Limitations

Combined testing delivers great efficiency: patients complete just one IVF cycle and one biopsy, while gaining full genetic details of every embryo.

That said, it comes with higher costs and demands a lab equipped with advanced NGS technology. Also, since PGT-M requires custom genetic probes, several weeks of advance planning are needed.

Success Rates Compared: PGT-A vs PGT-M

Understanding PGT-A vs PGT-M success rates by age can help you set realistic expectations.

PGT-M Success Rate for Single Gene Disorders

Clinical outcomes for PGT-A and PGT-M are well validated in recent large-scale studies.

A 2025 study in the Journal of Assisted Reproduction and Genetics analyzing 572 PGT-M IVF cycles recorded a 51.3% clinical pregnancy rate and a 44.8% live birth rate per embryo transfer.

A separate 2025 study in Archives of Gynecology and Obstetrics confirmed the overall superiority of PGT-assisted IVF over conventional IVF, with a 46.12% live birth rate for the PGT group versus 34.74% for standard IVF.

Among all PGT subtypes, PGT-A delivered the strongest performance, achieving a 48.28% live birth rate.

PGT-A vs PGT-M Success Rates by Age

There is a clear contrast in PGT-A vs PGT-M success rates by age. Maternal age strongly influences PGT-A performance but barely affects PGT-M outcomes.

Since PGT-M targets fixed familial single-gene mutations, its success rates remain stable across all age groups.

In comparison, PGT-A addresses age-related chromosomal errors, so its clinical benefits are highly age-dependent.

The advantages of PGT-A are especially prominent in PGT-A vs PGT-M success rates for women over 40. Advanced maternal age causes a sharp decline in euploid embryo ratios, dropping from 60-70% in women under 35 to roughly 20% after age 40 and only 10% after age 44.

A large-scale 2024 Fertility and Sterility study proved that women aged 38 and above benefit the most from PGT-A, with good-prognosis patients aged 38-40 seeing a 14% relative increase in cumulative live birth rates with PGT-A screening.

Beyond advanced age groups, PGT-A also delivers remarkable improvements for patients with recurrent pregnancy loss (RPL). Corresponding meta-analysis data further validated that it effectively elevates pregnancy and live birth outcomes while reducing miscarriage risks.